

SB0248S01 compared with SB0248

~~{Omitted text}~~ shows text that was in SB0248 but was omitted in SB0248S01

inserted text shows text that was not in SB0248 but was inserted into SB0248S01

DISCLAIMER: This document is provided to assist you in your comparison of the two bills. Sometimes this automated comparison will NOT be completely accurate. Therefore, you need to read the actual bills. This automatically generated document could contain inaccuracies caused by: limitations of the compare program; bad input data; or other causes.

1

Controlled Substances Amendments

2025 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Kirk A. Cullimore

House Sponsor:

2

3 **LONG TITLE**

4 **General Description:**

5 This bill amends provisions related to certain controlled substances.

6 **Highlighted Provisions:**

7 This bill:

- 8 ▶ amends provisions related to providing psilocybin and methylenedioxymethamphetamine;
- 9 ▶ provides for the automatic rescheduling a certain type of psilocybin if rescheduled by the federal government; and
- 11 ▶ extends a repeal date.

12 **Money Appropriated in this Bill:**

13 None

14 **Other Special Clauses:**

15 None

17 **AMENDS:**

18 **58-37-3.5** , as enacted by Laws of Utah 2024, Chapter 539 , as enacted by Laws of Utah 2024,
Chapter 539

SB0248

SB0248 compared with SB0248S01

19 **58-37-4** , as last amended by Laws of Utah 2024, Chapter 298 , as last amended by Laws of Utah
2024, Chapter 298

20 **63I-1-258** , as last amended by Laws of Utah 2024, Third Special Session, Chapter 5 , as last
amended by Laws of Utah 2024, Third Special Session, Chapter 5

21

22 *Be it enacted by the Legislature of the state of Utah:*

23 Section 1. Section **58-37-3.5** is amended to read:

24 **58-37-3.5. Drugs for behavioral health treatment.**

25 (1) As used in this section:

26 (a) "Drug" means any form of psilocybin or methylenedioxymethamphetamine that is in federal Food
and Drug Administration Phase 3 testing for an investigational drug described in 21 C.F.R. Part 312,
or a natural or otherwise digestible state.

29 (b) "Health_care [system] provider" means:

30 ~~[(i) a privately-owned, non-profit, vertically-integrated health{-}care system that operates at least 15
licensed hospitals in the state; {f} or]~~

32 ~~[(ii) a health care system closely affiliated with an institution of higher education described in Section
53B-2-101{f} .]~~

34 (i) a cancer treatment center with a palliative care provider licensed under this title who has been living
in the state for at least five years; or

36 (ii) a licensed psychiatrist who has experience administering a drug in a legal clinical trial.

38 (2) {;}

34 ~~{(iii) a palliative care provider licensed under this title who has been living in the state for at least five
years; or}~~

36 ~~{(iv) {a licensed psychiatrist who has been licensed under this title for at least five years and living in
the state for at least five years.}}~~

38 ~~{(2)}~~ A health_care [system] provider may develop a behavioral health treatment program that includes
a treatment based on a drug that the health_care [system] provider determines is supported by a
broad collection of scientific and medical research.

41 (3) A health_care [system] provider described in Subsection (2):

42

SB0248 compared with SB0248S01

- (a) shall ensure that a drug used under the exclusive authority of this section is used by a patient only under the ~~[direct]~~ indirect supervision and control of the ~~[healthcare system and the healthcare system's health care providers who are licensed under this title]~~ health care provider; and
- 46 (b) may not provide treatments that are authorized exclusively under this section to an individual who is not at least 18 years old.
- 48 (4) Before July 1, ~~[2026]~~ 2027, a health_care ~~[system]~~ provider that creates a behavioral health treatment program under this section shall provide a written report to the Health and Human Services Interim Committee regarding:
- 51 (a) drugs used;
- 52 (b) health outcomes of patients;
- 53 (c) side effects of any drugs used; and
- 54 (d) any other information necessary for the Legislature to evaluate the medicinal value of any drugs.
- 56 (5) An individual or entity that complies with this section when using, distributing, possessing, administering, or supervising the use of, a drug is not guilty of a violation of this title.
- 59 Section 2. Section **58-37-4** is amended to read:
- 60 **58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules.**
- 62 (1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which consist of substances listed in this section.
- 64 (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated:
- 66 (a) Schedule I:
- 67 (i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation:
- 71 (A) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
- 73 (B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
- 74 (C) Acetylmethadol;
- 75 (D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide);
- 76 (E) Allylprodine;

SB0248 compared with SB0248S01

- 77 (F) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
- 79 (G) Alphameprodine;
- 80 (H) Alphamethadol;
- 81 (I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
- 83 (J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4- piperidinyl]-N-phenylpropanamide);
- 85 (K) Benzylpiperazine;
- 86 (L) Benzethidine;
- 87 (M) Betacetylmethadol;
- 88 (N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- piperidinyl]-N-phenylpropanamide);
- 90 (O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2- phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
- 92 (P) Betameprodine;
- 93 (Q) Betamethadol;
- 94 (R) Betaprodine;
- 95 (S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide);
- 96 (T) Clonitazene;
- 97 (U) Cyclopropyl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
- 99 (V) Dextromoramide;
- 100 (W) Diampromide;
- 101 (X) Diethylthiambutene;
- 102 (Y) Difenoxin;
- 103 (Z) Dimenoxadol;
- 104 (AA) Dimepheptanol;
- 105 (BB) Dimethylthiambutene;
- 106 (CC) Dioxaphetyl butyrate;
- 107 (DD) Dipipanone;
- 108 (EE) Ethylmethylthiambutene;
- 109 (FF) Etizolam (1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4-diazepine);
- 111 (GG) Etonitazene;

SB0248 compared with SB0248S01

- 112 (HH) Etoperidine;
- 113 (II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] furan-2-carboxamide);
- 115 (JJ) Furethidine;
- 116 (KK) Hydroxypethidine;
- 117 (LL) Ketobemidone;
- 118 (MM) Levomoramide;
- 119 (NN) Levophenacetylmorphan;
- 120 (OO) Methoxyacetyl fentanyl (2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide);
- 122 (PP) Morpheridine;
- 123 (QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 124 (RR) Noracymethadol;
- 125 (SS) Norlevorphanol;
- 126 (TT) Normethadone;
- 127 (UU) Norpipanone;
- 128 (VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl] propanamide);
- 130 (WW) Para-fluoroisobutyryl fentanyl (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
- 132 (XX) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 133 (YY) Phenadoxone;
- 134 (ZZ) Phenampromide;
- 135 (AAA) Phenomorphan;
- 136 (BBB) Phenoperidine;
- 137 (CCC) Piritramide;
- 138 (DDD) Proheptazine;
- 139 (EEE) Properidine;
- 140 (FFF) Propiram;
- 141 (GGG) Racemoramide;
- 142 (HHH) Tetrahydrofuran fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide);
- 144 (III) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide);
- 145 (JJJ) Tilidine;

SB0248 compared with SB0248S01

- 146 (KKK) Trimeperidine;
- 147 (LLL) 3-methylfentanyl, including the optical and geometric isomers (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide);
- 149 (MMM) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- 151 (NNN) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also known as U-47700;
and
- 153 (OOO) 4-cyano CUMYL-BUTINACA.
- 154 (ii) Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
- 158 (A) Acetorphine;
- 159 (B) Acetyldihydrocodeine;
- 160 (C) Benzylmorphine;
- 161 (D) Codeine methylbromide;
- 162 (E) Codeine-N-Oxide;
- 163 (F) Cyprenorphine;
- 164 (G) Desomorphine;
- 165 (H) Dihydromorphine;
- 166 (I) Drotebanol;
- 167 (J) Etorphine (except hydrochloride salt);
- 168 (K) Heroin;
- 169 (L) Hydromorphanol;
- 170 (M) Methyldesorphine;
- 171 (N) Methylhydromorphine;
- 172 (O) Morphine methylbromide;
- 173 (P) Morphine methylsulfonate;
- 174 (Q) Morphine-N-Oxide;
- 175 (R) Myorphine;
- 176 (S) Nicocodeine;
- 177 (T) Nicomorphine;
- 178 (U) Normorphine;

SB0248 compared with SB0248S01

- 179 (V) Pholcodine; and
180 (W) Thebacon.
- 181 (iii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation; as used in this Subsection (2) (a)(iii) only, "isomer" includes the optical, position, and geometric isomers:
- 187 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;
- 189 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: 4-bromo-2,5-dimethoxy- α -methylphenethylamine; 4-bromo-2,5-DMA;
- 191 (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
- 194 (D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy- α -methylphenethylamine; 2,5-DMA;
- 196 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
- 197 (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy- α -methylphenethylamine; paramethoxyamphetamine, PMA;
- 199 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
- 200 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: 4-methyl-2,5-dimethoxy- α -methylphenethylamine; "DOM"; and "STP";
- 202 (I) 3,4-methylenedioxy amphetamine;
- 203 (J) 3,4-methylenedioxymethamphetamine (MDMA);
- 204 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl- alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
- 207 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
- 210 (M) 3,4,5-trimethoxy amphetamine;
- 211 (N) Bufotenine, some trade and other names: 3-(β -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;

SB0248 compared with SB0248S01

- 214 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
- 215 (P) Dimethyltryptamine, some trade or other names: DMT;
- 216 (Q) Ibogaine, some trade and other names: 7-Ethyl-6,6 β ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino [5,4-b] indole; Tabernanthe iboga;
- 219 (R) Lysergic acid diethylamide;
- 220 (S) Marijuana;
- 221 (T) Mescaline;
- 222 (U) Parahexyl, some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
- 225 (V) Peyote, meaning all parts of the plant presently classified botanically as *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
- 230 (W) N-ethyl-3-piperidyl benzilate;
- 231 (X) N-methyl-3-piperidyl benzilate;
- 232 (Y) Psilocybin, except as provided in Subsection (3);
- 233 (Z) Psilocyn;
- 234 (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus *Cannabis* (cannabis plant), except for marijuana as defined in Subsection 58-37-2(1)(aa)(i)(E), as well as synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of *Cannabis*, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following: Δ 1 cis or trans tetrahydrocannabinol, and their optical isomers Δ 6 cis or trans tetrahydrocannabinol, and their optical isomers Δ 3,4 cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered;
- 245 (BB) Ethylamine analog of phencyclidine, some trade or other names: N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;
- 248 (CC) Pyrrolidine analog of phencyclidine, some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;

SB0248 compared with SB0248S01

- 250 (DD) Thiophene analog of phencyclidine, some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-
piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and
- 253 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.
- 254 (iv) Unless specifically excepted or unless listed in another schedule, any material compound, mixture,
or preparation which contains any quantity of the following substances having a depressant effect on
the central nervous system, including its salts, isomers, and salts of isomers when the existence of
the salts, isomers, and salts of isomers is possible within the specific chemical designation:
- 259 (A) Mecloqualone; and
- 260 (B) Methaqualone.
- 261 (v) Any material, compound, mixture, or preparation containing any quantity of the following
substances having a stimulant effect on the central nervous system, including their salts, isomers,
and salts of isomers:
- 264 (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-
phenyl-2-oxazolamine;
- 266 (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone,
2-aminopropiophenone, and norephedrone;
- 268 (C) Fenethylamine;
- 269 (D) Methcathinone, some other names: 2-(methylamino)-propionophenone; alpha-
(methylamino)propionophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-
methylaminopropionophenone; monomethylpropion; ephedrone; N-methylcathinone;
methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
optical isomers;
- 274 (E) (\pm)cis-4-methylaminorex ((\pm)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
- 275 (F) N-ethylamphetamine; and
- 276 (G) N,N-dimethylamphetamine, also known as N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-
trimethylphenethylamine.
- 278 (vi) Any material, compound, mixture, or preparation which contains any quantity of the following
substances, including their optical isomers, salts, and salts of isomers, subject to temporary
emergency scheduling:
- 281 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
- 282 (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).

SB0248 compared with SB0248S01

- 283 (vii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
- 287 (b) Schedule II:
- 288 (i) Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
- 292 (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including:
- 295 (I) Raw opium;
- 296 (II) Opium extracts;
- 297 (III) Opium fluid;
- 298 (IV) Powdered opium;
- 299 (V) Granulated opium;
- 300 (VI) Tincture of opium;
- 301 (VII) Codeine;
- 302 (VIII) Ethylmorphine;
- 303 (IX) Etorphine hydrochloride;
- 304 (X) Hydrocodone;
- 305 (XI) Hydromorphone;
- 306 (XII) Metopon;
- 307 (XIII) Morphine;
- 308 (XIV) Oxycodone;
- 309 (XV) Oxymorphone; and
- 310 (XVI) Thebaine;
- 311 (B) Any salt, compound, derivative, or preparation which is chemically equivalent or identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these substances may not include the isoquinoline alkaloids of opium;
- 315 (C) Opium poppy and poppy straw;

SB0248 compared with SB0248S01

- 316 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation which is chemically equivalent or identical with any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives, whether derived from the coca plant or synthetically produced, except the substances may not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; and
- 323 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
- 326 (ii) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation, except dextrorphan and levopropoxyphene:
- 331 (A) Alfentanil;
- 332 (B) Alphaprodine;
- 333 (C) Anileridine;
- 334 (D) Bezitramide;
- 335 (E) Bulk dextropropoxyphene (nondosage forms);
- 336 (F) Carfentanil;
- 337 (G) Dihydrocodeine;
- 338 (H) Diphenoxylate;
- 339 (I) Fentanyl;
- 340 (J) Isomethadone;
- 341 (K) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
- 343 (L) Levomethorphan;
- 344 (M) Levorphanol;
- 345 (N) Metazocine;
- 346 (O) Methadone;
- 347 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
- 348 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid;
- 350 (R) Pethidine (meperidine);

SB0248 compared with SB0248S01

- 351 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 352 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 353 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 354 (V) Phenazocine;
- 355 (W) Piminodine;
- 356 (X) Racemethorphan;
- 357 (Y) Racemorphan;
- 358 (Z) Remifentanyl; and
- 359 (AA) Sufentanyl.
- 360 (iii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:
- 363 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
- 364 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
- 365 (C) Phenmetrazine and its salts; and
- 366 (D) Methylphenidate.
- 367 (iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
- 372 (A) Amobarbital;
- 373 (B) Glutethimide;
- 374 (C) Pentobarbital;
- 375 (D) Phencyclidine;
- 376 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile (PCC); and
- 378 (F) Secobarbital.
- 379 (v)
- (A) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of Phenylacetone.
- 382

SB0248 compared with SB0248S01

- (B) Some of these substances may be known by trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
- 384 (vi) Nabilone, another name for nabilone: (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
- 387 (vii) A drug product or preparation that contains any component of marijuana, including tetrahydrocannabinol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 391 (c) Schedule III:
- 392 (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:
- 398 (A) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;
- 404 (B) Benzphetamine;
- 405 (C) Chlorphentermine;
- 406 (D) Clortermine; and
- 407 (E) Phendimetrazine.
- 408 (ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:
- 411 (A) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients which are not listed in any schedule;
- 414

SB0248 compared with SB0248S01

- (B) Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital, or any salt of any of these drugs which is approved by the United States Food and Drug Administration for marketing only as a suppository;
- 417 (C) Any substance which contains any quantity of a derivative of barbituric acid or any salt of any of them;
- 419 (D) Chlorhexadol;
- 420 (E) Buprenorphine;
- 421 (F) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under the federal Food, Drug, and Cosmetic Act, Section 505;
- 424 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine: \pm -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
- 426 (H) Lysergic acid;
- 427 (I) Lysergic acid amide;
- 428 (J) Methyprylon;
- 429 (K) Sulfondiethylmethane;
- 430 (L) Sulfonethylmethane;
- 431 (M) Sulfonmethane; and
- 432 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one, flupyrazapon.
- 438 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product, some other names for dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)-delta-9-(trans)-tetrahydrocannabinol.
- 443 (iv) Nalorphine.
- 444 (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
- 448

SB0248 compared with SB0248S01

- (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
- 451 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;
- 454 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
- 457 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;
- 460 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts;
- 463 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts;
- 466 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; and
- 469 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts.
- 472 (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids including any of the following or any isomer, ester, salt, or derivative of the following that promotes muscle growth:
 - 475 (A) Boldenone;
 - 476 (B) Chlorotestosterone (4-chlortestosterone);
 - 477 (C) Clostebol;
 - 478 (D) Dehydrochlormethyltestosterone;
 - 479 (E) Dihydrotestosterone (4-dihydrotestosterone);
 - 480 (F) Drostanolone;
 - 481 (G) Ethylestrenol;
 - 482 (H) Fluoxymesterone;
 - 483 (I) Formebolone (formebolone);
 - 484 (J) Mesterolone;

SB0248 compared with SB0248S01

- 485 (K) Methandienone;
486 (L) Methandranone;
487 (M) Methandriol;
488 (N) Methandrostenolone;
489 (O) Methenolone;
490 (P) Methyltestosterone;
491 (Q) Mibolerone;
492 (R) Nandrolone;
493 (S) Norethandrolone;
494 (T) Oxandrolone;
495 (U) Oxymesterone;
496 (V) Oxymetholone;
497 (W) Stanolone;
498 (X) Stanozolol;
499 (Y) Testolactone;
500 (Z) Testosterone; and
501 (AA) Trenbolone.
- 502 (vii) Anabolic steroids expressly intended for administration through implants to cattle or other nonhuman species, and approved by the Secretary of Health and Human Services for use, may not be classified as a controlled substance.
- 505 (viii) A drug product or preparation that contains any component of marijuana, including tetrahydrocannabinol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 509 (ix) Nabiximols.
- 510 (d) Schedule IV:
- 511 (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.
- 515 (ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers,

SB0248 compared with SB0248S01

and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

- 520 (A) Alprazolam;
- 521 (B) Barbital;
- 522 (C) Bromazepam;
- 523 (D) Butorphanol;
- 524 (E) Camazepam;
- 525 (F) Carisoprodol;
- 526 (G) Chloral betaine;
- 527 (H) Chloral hydrate;
- 528 (I) Chlordiazepoxide;
- 529 (J) Clobazam;
- 530 (K) Clonazepam;
- 531 (L) Clorazepate;
- 532 (M) Clotiazepam;
- 533 (N) Cloxazolam;
- 534 (O) Delorazepam;
- 535 (P) Diazepam;
- 536 (Q) Dichloralphenazone;
- 537 (R) Estazolam;
- 538 (S) Ethchlorvynol;
- 539 (T) Ethinamate;
- 540 (U) Ethyl loflazepate;
- 541 (V) Fludiazepam;
- 542 (W) Flunitrazepam;
- 543 (X) Flurazepam;
- 544 (Y) Halazepam;
- 545 (Z) Haloxazolam;
- 546 (AA) Ketazolam;
- 547 (BB) Loprazolam;
- 548 (CC) Lorazepam;

SB0248 compared with SB0248S01

- 549 (DD) Lormetazepam;
- 550 (EE) Mebutamate;
- 551 (FF) Medazepam;
- 552 (GG) Meprobamate;
- 553 (HH) Methohexital;
- 554 (II) Methylphenobarbital (mephobarbital);
- 555 (JJ) Midazolam;
- 556 (KK) Nimetazepam;
- 557 (LL) Nitrazepam;
- 558 (MM) Nordiazepam;
- 559 (NN) Oxazepam;
- 560 (OO) Oxazolam;
- 561 (PP) Paraldehyde;
- 562 (QQ) Pentazocine;
- 563 (RR) Petrichloral;
- 564 (SS) Phenobarbital;
- 565 (TT) Pinazepam;
- 566 (UU) Prazepam;
- 567 (VV) Quazepam;
- 568 (WW) Temazepam;
- 569 (XX) Tetrazepam;
- 570 (YY) Tramadol;
- 571 (ZZ) Triazolam;
- 572 (AAA) Zaleplon; and
- 573 (BBB) Zolpidem.
- 574 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains any quantity of the following substances, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible.
- 578 (iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric

SB0248 compared with SB0248S01

isomers, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

- 584 (A) Cathine ((+)-norpseudoephedrine);
- 585 (B) Diethylpropion;
- 586 (C) Fencamfamine;
- 587 (D) Fenproporex;
- 588 (E) Mazindol;
- 589 (F) Mefenorex;
- 590 (G) Modafinil;
- 591 (H) Pemoline, including organometallic complexes and chelates thereof;
- 592 (I) Phentermine;
- 593 (J) Pipradrol;
- 594 (K) Sibutramine; and
- 595 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
- 596 (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.
- 600 (vi) A drug product or preparation that contains any component of marijuana and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule IV of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 604 (e) Schedule V:
- 605 (i) Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
 - 610 (A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;
 - 611 (B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;
 - 613 (C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;
 - 615 (D) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;

SB0248 compared with SB0248S01

- 617 (E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
- 618 (F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; and
- 620 (G) unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.
- 624 (ii) A drug product or preparation that contains any component of marijuana, including cannabidiol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513.
- 628 (iii) Gabapentin.
- 629 (3) If the federal government schedules the pharmaceutical composition of crystalline polymorph psilocybin in a schedule that is not schedule I, that composition is deemed scheduled under this section in the same schedule that the composition is scheduled under 21 U.S.C. Sec. 812 and 21 C.F.R. Sec. 1308.14.
- 633 Section 3. Section **63I-1-258** is amended to read:
- 634 **63I-1-258. Repeal dates: Title 58.**
- 635 (1) Title 58, Chapter 13, Health Care Providers Immunity from Liability Act, is repealed July 1, 2026.
- 637 (2) Title 58, Chapter 15, Health Facility Administrator Act, is repealed July 1, 2025.
- 638 (3) Title 58, Chapter 20b, Environmental Health Scientist Act, is repealed July 1, 2028.
- 639 (4) Section 58-37-3.5, Drugs for behavioral health treatment, is repealed July 1, [2027] 2029.
- 640 (5) Subsection 58-37-6(7)(f)(iii), regarding a seven-day opiate supply restriction, is repealed July 1, 2032.
- 642 (6) Title 58, Chapter 40, Recreational Therapy Practice Act, is repealed July 1, 2033.
- 643 (7) Title 58, Chapter 41, Speech-Language Pathology and Audiology Licensing Act, is repealed July 1, 2029.
- 645 (8) Title 58, Chapter 46a, Hearing Instrument Specialist Licensing Act, is repealed July 1, 2033.
- 647 (9) Title 58, Chapter 47b, Massage Therapy Practice Act, is repealed July 1, 2034.
- 648 (10) Subsection 58-55-201(2), regarding the Alarm System and Security Licensing Advisory Board, is repealed July 1, 2027.
- 650 (11) Title 58, Chapter 61, Part 7, Behavior Analyst Licensing Act, is repealed July 1, 2026.

SB0248 compared with SB0248S01

651 Section 4. **Effective date.**

This bill takes effect on May 7, 2025.

2-25-25 10:02 AM